Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy

Clinical Breast Cancer

Volumn 16, Issue 3, 2016, Pages 188-195

  Telford, Claire ^a   Jones, Nick ^a   Livings, Christopher ^b   Batson, Sarah ^b  

^a ASTRAZENECA   (United Kingdom)

^b Decision Resources Group   (United Kingdom)

Author keywords

Aromatase inhibitor; Hormone therapy; Indirect treatment comparison; Progression; Selective estrogen receptor degrader

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BAYES THEOREM; CANCER HORMONE THERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG THERAPY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; MORTALITY; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; EVEROLIMUS; FEMALE; HUMANS; MEGESTROL ACETATE; NETWORK META-ANALYSIS; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84959891034     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2016.02.007     Document Type: Article

References (26)

1. F. Cardoso, A. Costa, L. Norton, and et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 2014 1871 1888
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, version 2 2015: Breast Cancer. 2 Mar 2015 update. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed: Aug 25, 2015.
3. J.F.R. Robertson Fulvestrant (Faslodex) - how to make a good drug better Oncologist 12 2007 774 784
4. European Medicines Agency. Fulvestrant summary of product characteristics. 19 May 2015 update. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000540/WC500021174.pdf. Accessed: Sep 8, 2015.
5. US Food and Drug Administration. Fulvestrant prescribing information. 19 May 2015 update. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021344s015lbl.pdf. Accessed: Aug 30, 2015.
6. A. Di Leo, G. Jerusalem, L. Petruzelka, and et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 2010 4594 4600
7. A. Di Leo, G. Jerusalem, L. Petruzelka, and et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial J Natl Cancer Inst 106 2014 djt337
8. A.M. Glenny, D.G. Altman, F. Song, and et al. Indirect comparisons of competing interventions Health Technol Assess 9 2005 1 134
9. A. Sutton, A.E. Ades, N. Cooper, and et al. Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 26 2008 753 767
10. J.P. Jansen, and H. Naci Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers BMC Med 11 2013 159
11. T. Bachelot, R. McCool, S. Duffy, and et al. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis Breast Cancer Res Treat 143 2014 125 133
12. S. Cope, M.J. Ouwens, J.P. Jansen, and et al. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models Value Health 16 2013 403 417
13. E.D. Saad, and M. Buyse Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 30 2012 1750 1754
14. Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Published June 2011. Mar 2013 update. Available at: http://www.nicedsu.org.uk/Survival-analysis-TSD(2892878).htm. Accessed: Aug 25, 2015.
15. P. Guyot, A.E. Ades, M.J. Ouwens, and et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves BMC Med Res Methodol 12 2012 9
16. D. Spiegelhalter, A. Thomas, N. Best, and et al. WinBUGS User Manual: version 1.4 2003 Available at: http://www.mrc-bsu.cam.ac.uk/wp-content/uploads/manual14.pdf. Accessed Aug 25, 2015.
17. A.U. Buzdar, W. Jonat, A. Howell, and et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group Cancer 83 1998 1142 1152
18. A. Buzdar, J. Douma, N. Davidson, and et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate J Clin Oncol 19 2001 3357 3366
19. C.K. Osborne, J. Pippen, S.E. Jones, and et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
20. A. Howell, J.F.R. Robertson, J. Quaresma Albano, and et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
21. S.R. Johnston, L.S. Kilburn, P. Ellis, and et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 2013 989 998
22. M. Piccart, G.N. Hortobagyi, M. Campone, and et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Ann Oncol 25 2014 2357 2362
23. J. Baselga, M. Campone, M. Piccart, and et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
24. M.J. Ellis, A. Llombart-Cussac, D. Feltl, and et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study J Clin Oncol 33 2015 3781 3787
25. R.S. Finn, J.P. Crown, I. Lang, and et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 2015 25 35
26. N.C. Turner, J. Ro, F. André, and et al. Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373 2015 209 219